Immunome (NASDAQ:IMNM) Releases Earnings Results, Beats Expectations By $0.14 EPS

Immunome (NASDAQ:IMNM - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.14, Zacks reports. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The business had revenue of $2.93 million during the quarter, compared to analysts' expectations of $0.46 million.

Immunome Trading Up 6.4%

Shares of Immunome stock opened at $7.94 on Tuesday. The business's fifty day moving average price is $7.73 and its 200 day moving average price is $9.91. Immunome has a twelve month low of $5.15 and a twelve month high of $16.81. The stock has a market capitalization of $690.88 million, a P/E ratio of -0.98 and a beta of 2.00.

Insider Transactions at Immunome

In other news, Director Jean Jacques Bienaime bought 7,000 shares of Immunome stock in a transaction dated Monday, March 24th. The shares were acquired at an average cost of $8.21 per share, with a total value of $57,470.00. Following the completion of the transaction, the director now owns 23,615 shares in the company, valued at approximately $193,879.15. This trade represents a 42.13% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CTO Philip Tsai acquired 12,300 shares of the business's stock in a transaction on Monday, March 24th. The stock was purchased at an average price of $8.42 per share, for a total transaction of $103,566.00. Following the acquisition, the chief technology officer now directly owns 33,300 shares in the company, valued at $280,386. This represents a 58.57% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders bought 156,400 shares of company stock worth $1,160,495. 8.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

IMNM has been the topic of a number of recent analyst reports. Stephens reaffirmed an "overweight" rating and issued a $30.00 target price on shares of Immunome in a research report on Thursday, March 20th. Guggenheim dropped their price objective on Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a report on Thursday, March 20th. Wedbush reissued an "outperform" rating and issued a $33.00 target price on shares of Immunome in a report on Thursday, March 20th. Lake Street Capital started coverage on Immunome in a research report on Wednesday, April 2nd. They issued a "buy" rating and a $23.00 target price for the company. Finally, Lifesci Capital began coverage on Immunome in a research report on Tuesday, March 11th. They set an "outperform" rating and a $20.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Immunome has a consensus rating of "Buy" and an average price target of $25.33.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.